Suchergebnisse - "Kiesewetter, B"

PubPharm (20)

1

ESMO-Magnitude of Clinical Benefit Scale for haematological malignancies (ESMO-MCBS:H) version 1.0

enthalten in: Annals of oncology : official journal of the European Society for Medical Oncology | 2023

von Kiesewetter, B. | Dafni, U. | de Vries, E. | +21

2

Methodological and reporting standards for quality-of-life data eligible for European Society for Medical Oncology-Magnitude of Clinical Benefit Scale (ESMO-MCBS) credit

enthalten in: Annals of oncology : official journal of the European Society for Medical Oncology | 2023

von Oosting, S. | Barriuso, J. | Bottomley, A. | +13

3

Pulmonary neuroendocrine tumours and somatostatin receptor status : an assessment of unlicensed use of somatostatin analogues in the clinical practice

enthalten in: ESMO open | 2022

von Kiesewetter, B. | Mazal, P. | Kretschmer-Chott, E. | +2

4

Corrigendum to 'How I treat medullary thyroid cancer' : [ESMO Open Volume 6, Issue 3, June 2021, 100183

enthalten in: ESMO open | 2022

von Kiesewetter, B. | Riss, P. | Scheuba, C. | +1

ErratumFor: ESMO Open. 2021 Jun;6(3):100183. - PMID 34091261

5

Managing hematological cancer patients during the COVID-19 pandemic : an ESMO-EHA Interdisciplinary Expert Consensus

enthalten in: ESMO open | 2022

von Buske, C. | Dreyling, M. | Alvarez-Larrán, A. | +33

6

Biases in study design, implementation, and data analysis that distort the appraisal of clinical benefit and ESMO-Magnitude of Clinical Benefit Scale (ESMO-MCBS) scoring

enthalten in: ESMO open | 2021

von Gyawali, B. | de Vries, E. | Dafni, U. | +20

7

How I treat medullary thyroid cancer

enthalten in: ESMO open | 2021

von Kiesewetter, B. | Riss, P. | Scheuba, C. | +1

ErratumIn: ESMO Open. 2022 Jun;7(3):100516. - PMID 35688063

8

FIRST LINE SYSTEMIC TREATMENT IN MUCOSA‐ASSOCIATED LYMPHOID TISSUE (MALT) LYMPHOMA NOT ELIGIBLE FOR H. PYLORI ERADICATION – DO WE NEED CHEMOTHERAPY?

enthalten in: Hematological Oncology | 2019

von Kiesewetter, B. | Lamm, W. | Mayerhoefer, M. | +4

9

EARLY PROGRESSION OF DISEASE (POD24) PREDICTS SHORTER SURVIVAL IN MALT LYMPHOMA PATIENTS RECEIVING SYSTEMIC TREATMENT

enthalten in: Hematological Oncology | 2019

von Conconi, A. | Thieblemont, C. | Cascione, L. | +9

10

DEPTH OF REMISSION FOLLOWING FIRST LINE HP‐ERADICATION IS AN INDEPENDENT PROGNOSTIC FACTOR IN GASTRIC MALT LYMPHOMA

enthalten in: Hematological Oncology | 2019

von Raderer, M. | Dolak, W. | Simonitsch‐Klupp, I. | +1